Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress

Many now believe the holy grail for the next stage of therapeutic advance surrounds the development of disease-modifying approaches aimed at intercepting the year-on-year neurodegenerative decline experienced by most patients with Parkinson’s disease (PD). Based on recommendations of an internationa...

Descripción completa

Detalles Bibliográficos
Autores principales: Carroll, Camille B., Wyse, Richard K.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676977/
https://www.ncbi.nlm.nih.gov/pubmed/29036837
http://dx.doi.org/10.3233/JPD-171203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676977/
https://www.ncbi.nlm.nih.gov/pubmed/29036837
http://dx.doi.org/10.3233/JPD-171203

Ejemplares similares